188 related articles for article (PubMed ID: 30018130)
1. Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.
Rosenberg S; Ducray F; Alentorn A; Dehais C; Elarouci N; Kamoun A; Marie Y; Tanguy ML; De Reynies A; Mokhtari K; Figarella-Branger D; Delattre JY; Idbaih A;
Oncologist; 2018 Dec; 23(12):1500-1510. PubMed ID: 30018130
[TBL] [Abstract][Full Text] [Related]
2. Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.
Alentorn A; Dehais C; Ducray F; Carpentier C; Mokhtari K; Figarella-Branger D; Chinot O; Cohen-Moyal E; Ramirez C; Loiseau H; Elouahdani-Hamdi S; Beauchesne P; Langlois O; Desenclos C; Guillamo JS; Dam-Hieu P; Ghiringhelli F; Colin P; Godard J; Parker F; Dhermain F; Carpentier AF; Frenel JS; Menei P; Bauchet L; Faillot T; Fesneau M; Fontaine D; Motuo-Fotso MJ; Vauleon E; Gaultier C; Le Guerinel C; Gueye EM; Noel G; Desse N; Durando X; Barrascout E; Wager M; Ricard D; Carpiuc I; Delattre JY; Idbaih A;
Neurology; 2015 Oct; 85(15):1325-31. PubMed ID: 26385879
[TBL] [Abstract][Full Text] [Related]
3. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
[TBL] [Abstract][Full Text] [Related]
6. [IDHăTERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma].
Ji YC; Zhan YB; Liu XZ; Zhang ZY
Zhonghua Yi Xue Za Zhi; 2019 Jul; 99(25):1959-1962. PubMed ID: 31269600
[No Abstract] [Full Text] [Related]
7. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma.
Jiang H; Zhang Z; Ren X; Zeng W; Wang J; Lin S
J Neurosurg; 2016 Oct; 125(4):995-1001. PubMed ID: 26771849
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
10. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
11. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
13. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
Kanner AA; Staugaitis SM; Castilla EA; Chernova O; Prayson RA; Vogelbaum MA; Stevens G; Peereboom D; Suh J; Lee SY; Tubbs RR; Barnett GH
J Neurosurg; 2006 Apr; 104(4):542-50. PubMed ID: 16619658
[TBL] [Abstract][Full Text] [Related]
14. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas.
Richardson TE; Sathe AA; Xing C; Mirchia K; Viapiano MS; Snuderl M; Abdullah KG; Hatanpaa KJ; Walker JM
J Neuropathol Exp Neurol; 2021 Mar; 80(4):354-365. PubMed ID: 33755138
[TBL] [Abstract][Full Text] [Related]
15. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.
Idbaih A; Ducray F; Dehais C; Courdy C; Carpentier C; de Bernard S; Uro-Coste E; Mokhtari K; Jouvet A; Honnorat J; Chinot O; Ramirez C; Beauchesne P; Benouaich-Amiel A; Godard J; Eimer S; Parker F; Lechapt-Zalcman E; Colin P; Loussouarn D; Faillot T; Dam-Hieu P; Elouadhani-Hamdi S; Bauchet L; Langlois O; Le Guerinel C; Fontaine D; Vauleon E; Menei P; Fotso MJ; Desenclos C; Verrelle P; Ghiringhelli F; Noel G; Labrousse F; Carpentier A; Dhermain F; Delattre JY; Figarella-Branger D;
PLoS One; 2012; 7(10):e45950. PubMed ID: 23071531
[TBL] [Abstract][Full Text] [Related]
16. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
[TBL] [Abstract][Full Text] [Related]
17. Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer.
Zhang L; Yuan Y; Lu KH; Zhang L
BMC Bioinformatics; 2016 May; 17(1):222. PubMed ID: 27230211
[TBL] [Abstract][Full Text] [Related]
18. A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component.
Gadji M; Crous-Tsanaclis AM; Mathieu D; Mai S; Fortin D; Drouin R
Neuropathology; 2014 Apr; 34(2):170-8. PubMed ID: 24118308
[TBL] [Abstract][Full Text] [Related]
19. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay.
Nigro JM; Takahashi MA; Ginzinger DG; Law M; Passe S; Jenkins RB; Aldape K
Am J Pathol; 2001 Apr; 158(4):1253-62. PubMed ID: 11290543
[TBL] [Abstract][Full Text] [Related]
20. Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses.
Magnani I; Moroni RF; Roversi G; Beghini A; Pfundt R; Schoenmakers EF; Larizza L
Cancer Genet Cytogenet; 2005 Sep; 161(2):140-5. PubMed ID: 16102584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
